The insulin cap is right. Now fund the supply chain behind it.

A price ceiling without a supply plan is half a policy.

Analysts were divided on how durable the shift will prove.

The story, as ever, is in the distribution: who gains, who waits, and how long the advantage lasts once the initial momentum fades. That is the question this week leaves open.